Loading...

VYGR VOYAGER THERAPEUTICS INC Product Launches 8-K Filing

VYGR

VYGR

VOYAGER THERAPEUTICS INC

(VYGR)

2025 8-K

Show Summary

Show Summary

Financial Statements

Financial Results

ALS Program Update

Q3 Financial Results

License Agreement Update

Earnings Reports

Appointment of CFO

Annual Meeting of Stockholders

Phase 1a Trial Announcement

Financial Results

Departure of CFO and Appoin...

Appointment of Chief Medica...

Financial Results and Updates

Public Offering

License and Collaboration A...

Financial Results

Lease Agreement Amendment

Earnings Reports

Annual Meeting of Stockholders

Financial Results

Appointment of Director

Cash Holdings at Silicon Va...

Financial Results

Appointment of Director

Departure of Directors or C...

Collaboration Agreement

External Links:

Voyager Therapeutics is reassessing its gene therapy program for ALS due to new data, delaying its investigational drug application for VY9323, but expects to file other INDs in 2025 and 2026; it estimates its cash will last until mid-2027.

AI Assistant

VOYAGER THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.